logo    Company Page

Most Recent Insiders Activity

Transaction Date Company Name Insider Name (Title) Activity Stock Acquired or Disposed Shares Price range Amount
2024-06-05 Allogene Therapeutics, Inc. SATO VICKI L
(Director)
A Common Stock A 61475 $0.00 - $0.00 $0
2024-06-05 Allogene Therapeutics, Inc. Humer Franz B
(Director)
A Common Stock A 61475 $0.00 - $0.00 $0
2024-06-05 Allogene Therapeutics, Inc. MESSEMER DEBORAH M.
(Director)
A Common Stock A 122950 $0.00 - $0.00 $0
2024-05-30 Allogene Therapeutics, Inc. Humer Franz B
(Director)
S Common Stock D 11200 $2.34 - $2.34 $26,181
2024-05-16 Allogene Therapeutics, Inc. Belldegrun Arie
(Director)
P Common Stock A 1724137 $2.90 - $2.90 $4,999,997
2024-05-16 Allogene Therapeutics, Inc. Belldegrun Arie
(Director)
A Common Stock A 344828 $2.90 - $2.90 $1,000,001
2024-05-16 Allogene Therapeutics, Inc. Parker Geoffrey M.
(CHIEF FINANCIAL OFFICER)
A Common Stock A 344828 $2.90 - $2.90 $1,000,001
2024-05-16 Allogene Therapeutics, Inc. Chang David D
(President and CEO)
A Common Stock A 344828 $2.90 - $2.90 $1,000,001
2024-04-22 Allogene Therapeutics, Inc. MOORE TIMOTHY L.
(Chief Technical Officer)
F Common Stock D 17360 $3.47 - $3.47 $60,188
2024-03-14 Allogene Therapeutics, Inc. Chang David D
(President and CEO)
F Common Stock D 53393 $4.33 - $4.33 $231,191
2024-01-30 Allogene Therapeutics, Inc. Parker Geoffrey M.
(CHIEF FINANCIAL OFFICER)
P Common Stock A 190 $3.60 - $3.60 $683
2024-01-25 Allogene Therapeutics, Inc. MOORE TIMOTHY L.
(Chief Technical Officer)
A Common Stock A 96600 $0.00 - $0.00 $0
2024-01-25 Allogene Therapeutics, Inc. Douglas Earl Martin
(SVP, General Counsel)
A Common Stock A 41800 $0.00 - $0.00 $0
2024-01-25 Allogene Therapeutics, Inc. Parker Geoffrey M.
(CHIEF FINANCIAL OFFICER)
A Common Stock A 29400 $0.00 - $0.00 $0
2024-01-25 Allogene Therapeutics, Inc. Belldegrun Arie
(Director)
A Common Stock A 211973 $0.00 - $0.00 $0
2024-01-25 Allogene Therapeutics, Inc. Roberts Zachary
(EVP of R&D)
A Common Stock A 140000 $0.00 - $0.00 $0
2024-01-25 Allogene Therapeutics, Inc. Chang David D
(President and CEO)
A Common Stock A 317800 $0.00 - $0.00 $0
2024-01-22 Allogene Therapeutics, Inc. Roberts Zachary
(EVP of R&D)
F Common Stock D 24690 $3.17 - $3.17 $78,375
logo   

Please upgrade to premium to see all results. Signup if you don't have an account.

Login Signup
Activity types
A Grant, award or other acquisition
C Conversion of Derivative or Security
D Disposition to the issuer of issuer equity securities
E Expiration of short derivative position
F Payment of exercise price or tax liability
G Bona fide Gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary Transaction
J Other acquisition or disposition
K Transaction in equity swap or instrument with similar characteristics
L Small Acquisition
M Exercise or conversion of derivative security
O Exercise of out-of-the-money derivative security
P Open Market Purchase
S Open Market Sale
U Disposition pursuant to a tender of shares in a change of control transaction
V Transaction Voluntarily Reported
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust
Debug Info- Version: 2.6